title: [Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].
abstract: Chemotherapy options for the treatment of metastatic castration-resistant prostate cancer (CRPC) have been very limited for many decades. Until 2004, only mitoxantrone was approved, providing palliation, but no survival benefit. With the introduction of docetaxel, the landscape of chemotherapy for CRPC changed substantially. Prednisone and three-weekly docetaxel showed an overall survival (OS) benefit compared to mitoxantrone plus prednisone, in addition to a significant improvement of quality of life and pain reduction. Further strategies to treat CRPC with chemotherapy include reinduction with docetaxel in responding patients and the use of cabazitaxel, a novel semi-synthetic microtubule inhibitor, in the docetaxel-refractory population. This review article is meant to guide physicians through the optimal use of chemotherapy in CRPC patients in daily clinical practice.
authors.affiliation: 3. Medizinische Abteilung, Zentrum für Onkologie und Hämatologie, Angewandte Krebsforschung - Institution für Translationale Forschung Wien (ACR-ITR VIEnna), Kaiser Franz Josef-Spital - SMZ Süd, Kundratstraße 3, A-1100 Wien, Österreich. maria.desantis@wienkav.at
authors.forename: M
authors.initials: M
authors.lastname: De Santis
authors.forename: M
authors.initials: M
authors.lastname: Bachner
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D003131:Combined Modality Therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017211:Treatment Failure
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D004965:Estrogen Antagonists